Jacobs Levy Equity Management’s Allogene Therapeutics ALLO Stock Holding History

Jacobs Levy Equity Management’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.91M	Buy	+2,013,508	New	+$4.04M	0.02%	419
2024 Q3	–	Sell	-878,955	Closed	-$2.05M	–	945
2024 Q2	$2.05M	Buy	+878,955	New	+$2.59M	0.01%	592
2023 Q1	–	Sell	-11,217	Closed	-$70.6K	–	952
2022 Q4	$70.6K	Sell	11,217 -524,151	-98%	-$4.85M	﹤0.01%	930
2022 Q3	$5.78M	Buy	+535,368	New	+$7.28M	0.05%	360
2022 Q2	–	Sell	-270,737	Closed	-$2.47M	–	992
2022 Q1	$2.47M	Buy	+270,737	New	+$2.82M	0.02%	588

Other funds holding ALLO

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management's ALLO Position: Q1 2026 in Review

Jacobs Levy Equity Management opened a new position in Allogene Therapeutics (ALLO) in Q1 2026: 2,013,508 shares worth $4.91M. The stake represents 0.02% of the portfolio and ranks #419 among its holdings. This is a return to the name: Jacobs Levy Equity Management previously reported a position in ALLO as recently as Q2 2024.

Jacobs Levy Equity Management first reported a position in ALLO in Q1 2022 and has held it in 5 quarters since. The position peaked at $5.78M in Q3 2022. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

Jacobs Levy Equity Management held 2,013,508 shares of Allogene Therapeutics worth $4.91M as of Q1 2026.
Allogene Therapeutics was a new Jacobs Levy Equity Management position in Q1 2026.
Allogene Therapeutics made up 0.02% of Jacobs Levy Equity Management's portfolio in Q1 2026, its #419 holding.
Jacobs Levy Equity Management first reported a position in Allogene Therapeutics in Q1 2022 and has held it in 5 quarters since.
Jacobs Levy Equity Management's Allogene Therapeutics position peaked at $5.78M in Q3 2022.
208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.